Transdermal Cannabinoid Formulations for Steady MS Symptom Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for multiple sclerosis, muscle spasms, and pain associated with multiple sclerosis require frequent oral dosing, leading to side effects and inconvenience, while there is a need for a more effective and patient-friendly delivery system.
Innovation Solution
Transdermal delivery of THC and/or CBD through patches or compositions that provide continuous drug release, reducing dosing frequency and minimizing side effects by avoiding hepatic metabolism and maintaining steady plasma concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral dosing is used for multiple sclerosis treatment, then the drug can be administered systemically, but frequent dosing is required leading to side effects and inconvenience
Solution Approach 1:
The patent changes the administration route parameter from oral to transdermal, which fundamentally alters the pharmacokinetic profile. This enables sustained release over 72 hours or longer, reducing dosing frequency from multiple times daily to once weekly or less, thereby improving convenience and reducing side effects associated with frequent dosing
Solution Approach 2:
The transdermal delivery system provides continuous drug release over an extended period (72 hours to several weeks), maintaining steady plasma concentrations without the peak-and-trough fluctuations inherent in oral dosing. This continuous action ensures consistent therapeutic effect while reducing the need for frequent re-dosing
2Reliability
If oral dosing is used, then the drug reaches systemic circulation, but hepatic metabolism occurs leading to reduced efficacy and increased side effects
Solution Approach 1:
The patent introduces the skin and transdermal membrane as an intermediary delivery route, bypassing the gastrointestinal tract and liver first-pass metabolism. The drug is delivered directly into systemic circulation through the dermal layer, avoiding hepatic degradation and associated side effects while maintaining reliable therapeutic efficacy
Solution Approach 2:
The invention extracts the drug delivery pathway from the oral-gastrointestinal-liver route and replaces it with a transdermal route. This extraction removes the harmful hepatic metabolism step from the pharmacokinetic pathway, allowing the active compound to reach systemic circulation without being metabolized by the liver
3Reliability
If multiple oral doses are administered per day, then therapeutic levels are maintained, but patient compliance decreases due to inconvenience
Solution Approach 1:
The transdermal patch or implant is applied in advance and provides sustained drug release over 72 hours to several weeks without requiring patient intervention. The drug is pre-loaded into the delivery system, which then automatically maintains therapeutic levels through controlled diffusion or erosion, eliminating the need for daily or weekly patient actions
4Reliability
If oral cannabinoid products are used, then therapeutic effects are achieved, but psychoactive side effects occur
Solution Approach 1:
The patent changes the delivery parameters (route, rate, and timing) from oral to transdermal, which fundamentally alters the pharmacokinetic profile of cannabinoids. This enables lower, more consistent plasma concentrations to be achieved over extended periods, providing therapeutic effects while avoiding the peak concentrations that cause psychoactive side effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Transdermal delivery offers a convenient, less frequent dosing regimen with reduced side effects, providing sustained therapeutic effects for multiple sclerosis symptoms without peak and trough concentrations.
Implementation Method 1
Transdermal delivery of THC and/or CBD through patches or compositions that provide continuous drug release
Data Source
AI summary
The present disclosure relates to the to the transdermal administration of THC and/or CBD and derivatives of these compounds, for the treatment and/or prevention and/or control of multiple sclerosis, multiple sclerosis-related muscle spasms, and pain and/or spasticity in multiple sclerosis.